NPJ Vaccines最新文献_第6页

Seasonal influenza mRNA vaccine induces stronger innate and comparable or better adaptive responses than licensed inactivated vaccines. 季节性流感mRNA疫苗诱导比许可的灭活疫苗更强的先天性和可比或更好的适应性反应。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-26 DOI: 10.1038/s41541-026-01492-y

Erick Bermúdez-Méndez, Klara Lenart, Rodrigo Arcoverde Cerveira, Olivia Engstrand, Fredrika Hellgren, Alberto Cagigi, Sebastian Ols, Edith Jasny, Annika Reinhardt, Benjamin Petsch, Karin Loré

{"title":"Seasonal influenza mRNA vaccine induces stronger innate and comparable or better adaptive responses than licensed inactivated vaccines.","authors":"Erick Bermúdez-Méndez, Klara Lenart, Rodrigo Arcoverde Cerveira, Olivia Engstrand, Fredrika Hellgren, Alberto Cagigi, Sebastian Ols, Edith Jasny, Annika Reinhardt, Benjamin Petsch, Karin Loré","doi":"10.1038/s41541-026-01492-y","DOIUrl":"10.1038/s41541-026-01492-y","url":null,"abstract":"Seasonal vaccination is the most important strategy for mitigating the large disease burden caused by influenza virus. Licensed inactivated influenza virus vaccines rely on slow, egg-based production, underscoring the need for faster, more effective platforms that elicit robust immune responses. Here, we compare the immunogenicity of an unmodified mRNA-lipid nanoparticle vaccine encoding influenza hemagglutinin (HA) from A/Michigan/45/2015 (H1N1)pdm09, A/Singapore/INFIMH-16-0019/2016 (H3N2), B/Phuket/3073/2013 and B/Colorado/06/2017 with two approved, strain-matched, inactivated vaccines (Vaxigrip and Fluad) in non-human primates. The mRNA vaccine induced substantially stronger innate immune activation than Vaxigrip and Fluad, evidenced by rapid upregulation of genes involved in antiviral, antigen presentation and cell migration pathways, expansion of intermediate monocytes and increased secretion of pro-inflammatory cytokines. The mRNA vaccine elicited HA-specific antibodies against all four strains, with levels generally comparable to or exceeding those induced by Vaxigrip and Fluad, although this did not consistently translate to greater neutralizing capacity. Both the mRNA vaccine and Fluad generated higher frequencies of HA-specific memory B and T cell responses compared to Vaxigrip, with the mRNA vaccine inducing a particularly stronger response in the draining lymph nodes, potentially increasing antibody diversity and affinity. Altogether, these findings support the advancement of influenza mRNA vaccines as promising clinical candidates.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"11 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13212880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148033438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in funding for coronavirus vaccine research and development: implications for preparedness against future coronavirus threats. 冠状病毒疫苗研发经费趋势：对防范未来冠状病毒威胁的影响

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-26 DOI: 10.1038/s41541-026-01493-x

Derek Fleming, Emily Smith, Julie Ostrowsky, Angela Ulrich, Tabitha Leighton, Natalie Vestin, Angela J Mehr, Rodrigo Furst, Alice Norton, Eve Lackritz

引用次数: 0

Heterologous vaccination with a next-generation vaccinia virus and Ad26 induces Ebola-specific immunity in macaques. 用新一代牛痘病毒和Ad26进行异源疫苗接种可诱导猕猴产生埃博拉特异性免疫。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-23 DOI: 10.1038/s41541-026-01494-w

Aneesh Vijayan, Tamara Cooper, Marijn van der Neut Kolfschoten, Gary Heinemann, Mirjam Van Kampen, Satish Boedhoe, Harry van Diepen, Jan Serroyen, John Hayball, Leanne Hobbs, Anne Collins, Jerome Custers, Roland Zahn, Ronald Vogels

{"title":"Heterologous vaccination with a next-generation vaccinia virus and Ad26 induces Ebola-specific immunity in macaques.","authors":"Aneesh Vijayan, Tamara Cooper, Marijn van der Neut Kolfschoten, Gary Heinemann, Mirjam Van Kampen, Satish Boedhoe, Harry van Diepen, Jan Serroyen, John Hayball, Leanne Hobbs, Anne Collins, Jerome Custers, Roland Zahn, Ronald Vogels","doi":"10.1038/s41541-026-01494-w","DOIUrl":"10.1038/s41541-026-01494-w","url":null,"abstract":"Different ways of combining virus vector-based vaccines can impact the effectiveness of immune responses against specific antigens. In this study, we explored the effects of different immunization schedules on immune responses elicited by viral vector-based vaccines in monkeys, with a focus on the heterologous regimens with a next-generation attenuated vaccinia virus, Sementis Copenhagen vector (SCV), and human adenovirus serotype 26 (Ad26) expressing the Ebola glycoprotein (EBOV-GP). Our findings highlight that the order of administration of these vaccines plays a pivotal role in modulating cellular immune responses. We observed that initiating immunization with Ad26.EBOV followed by SCV.EBOV, significantly enhanced the magnitude and quality of antigen-specific memory CD4+ T-cell responses when compared to a homologous Ad26.EBOV regimen. Importantly, the binding antibody titers induced by this heterologous approach were similar to that elicited by a homologous Ad26.EBOV regimen, although we observed a transiently elevated neutralizing antibody titers at the peak of the response for the SCV.EBOV/Ad26.EBOV regimen. Our results suggest that a heterologous vaccination strategy combining Ad26.EBOV and SCV.EBOV could be an alternative to the currently used Ad26/MVA platform for Ebola vaccination, potentially mitigating some of the manufacturing challenges associated with Modified Vaccinia virus Ankara (MVA). The observed benefits of the heterologous regimen, particularly its capacity to enhance T-cell responses, reinforce its potential as a promising alternative to homologous regimens that warrants further investigation.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13473547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148006097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term cross-variant Fc-mediated immune responses against SARS-CoV-2 induced by a heterologous adenoviral/inactivated virus prime-boost vaccination strategy. 异源腺病毒/灭活病毒初增疫苗策略诱导的长期交叉变异fc介导的SARS-CoV-2免疫应答

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-22 DOI: 10.1038/s41541-026-01483-z

Doyoung Kim, Jung Hyuk Lee, Junhyeon Lee, Ju Yeon Park, Yuna Shin, Soo Ji Kim, BeomMin Cheon, Sumin Lee, Eunjin Cho, Deok Ryun Kim, Ryan P McNamara, Cheol-Heui Yun, Mohamadou Siribie, Asma Binte Aziz, Birkneh Tilahun Tadesse, Florian Marks, Sue Kyoung Jo, Hyon Jin Jeon, Raphaël Rakotozandrindrainy, Ilesh V Jani, Jae Seung Yang, Byoung-Shik Shim, Manki Song

{"title":"Long-term cross-variant Fc-mediated immune responses against SARS-CoV-2 induced by a heterologous adenoviral/inactivated virus prime-boost vaccination strategy.","authors":"Doyoung Kim, Jung Hyuk Lee, Junhyeon Lee, Ju Yeon Park, Yuna Shin, Soo Ji Kim, BeomMin Cheon, Sumin Lee, Eunjin Cho, Deok Ryun Kim, Ryan P McNamara, Cheol-Heui Yun, Mohamadou Siribie, Asma Binte Aziz, Birkneh Tilahun Tadesse, Florian Marks, Sue Kyoung Jo, Hyon Jin Jeon, Raphaël Rakotozandrindrainy, Ilesh V Jani, Jae Seung Yang, Byoung-Shik Shim, Manki Song","doi":"10.1038/s41541-026-01483-z","DOIUrl":"10.1038/s41541-026-01483-z","url":null,"abstract":"Limited vaccine availability and logistical barriers during the COVID-19 pandemic have hindered homologous boosting in resource-limited regions. Therefore, heterologous prime-boost regimens have gained attention as versatile and practical alternatives. We evaluated the immunogenicity and longevity of four vaccine regimens in adults from Mozambique and Madagascar: single-dose Ad26.COV2.S (Ad26.S), homologous BBIBP-CorV (BBIBP), and two heterologous combinations (BBIBP-Ad26.S and Ad26.S-BBIBP, in prime-boost order). Using systems serology, we characterized Fc-mediated antibody responses against SARS-CoV-2 wild-type and Omicron BA.1. Among all regimens, Ad26.S-BBIBP elicited broad and sustained humoral immunity for up to 6 months, with enhanced IgG levels, Fcγ receptor binding, and Fc-mediated effector functions. These responses declined more slowly than with single-Ad26.S. Compared to the other regimens, antibody-dependent natural killer cell activation (ADNKA) emerged as a distinct characteristic of durable cross-variant immunity in Ad26.S-BBIBP recipients. These findings highlight that the Ad26.S-BBIBP regimen is immunologically advantageous, with Fc-mediated effector functions, particularly ADNKA, representing an important characteristic of its relatively durable and cross-strain protection even as neutralizing antibody titers decline.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13572433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147988473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of naturally occurring and vaccine-induced Ad26 neutralizing antibodies in immunogenicity of Ad26-based vaccines. 自然产生的和疫苗诱导的Ad26中和抗体在Ad26基疫苗免疫原性中的作用

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-21 DOI: 10.1038/s41541-026-01488-8

Mariska G M van Rosmalen, Joris Menten, Daniel J Stieh, Nadine Salisch, Janine van Duijn, Arangassery Rosemary Bastian, Chelsea McLean, Viki Bockstal, Kim Stuyckens, Macaya Douoguih, An Vandebosch, Hanneke Schuitemaker, Jenny Hendriks

{"title":"The role of naturally occurring and vaccine-induced Ad26 neutralizing antibodies in immunogenicity of Ad26-based vaccines.","authors":"Mariska G M van Rosmalen, Joris Menten, Daniel J Stieh, Nadine Salisch, Janine van Duijn, Arangassery Rosemary Bastian, Chelsea McLean, Viki Bockstal, Kim Stuyckens, Macaya Douoguih, An Vandebosch, Hanneke Schuitemaker, Jenny Hendriks","doi":"10.1038/s41541-026-01488-8","DOIUrl":"10.1038/s41541-026-01488-8","url":null,"abstract":"Adenovirus 26 (Ad26) is frequently used as a vaccine vector targeting infectious diseases. Neutralizing antibodies (NAbs) induced by natural infection or immunization against some viral vaccine vectors may impact vaccine-induced immunogenicity and efficacy. We evaluated the natural seroprevalence and impact of Ad26 NAbs on vaccine immunogenicity using data combined from 21 clinical studies including 3851 participants from 15 countries. Ad26 NAb seroprevalence was higher in Africa than the United States and Europe. An inconsistently observed, clinically negligible negative trend was observed between naturally occurring Ad26 NAbs and vaccine-induced immune responses in participants who received Ad26-based Ebola or HIV vaccine regimens. Assessment of the impact of vaccine-induced anti-vector immunity after repeated vaccination found that an Ad26-based COVID-19 vaccine received 1-12 months before an Ad26-based RSV vaccine did not seem to impact post vaccination RSV immune responses. Within the study limitations, our data suggest that Ad26-based vaccines can be used in countries with high Ad26 seroprevalence and for repeated vaccination without compromising the vaccine antigen-induced immune response.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13462603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147988415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in Epstein-Barr virus vaccines development from mechanistic exploration to clinical translation. eb病毒疫苗从机制探索到临床转化的最新进展。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-20 DOI: 10.1038/s41541-026-01486-w

Liwei Hong, Juju Zhou, Junjuan Tan, Xiaoqian Zhu, Weihan Chen, Song Xie, Baotian Huang, Kai Chen

引用次数: 0

Vaccination in individuals with Down syndrome: immune vulnerability, safety, efficacy and opportunities. 唐氏综合征个体的疫苗接种：免疫脆弱性、安全性、有效性和机会。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-19 DOI: 10.1038/s41541-026-01489-7

Bernard Khor, Noemi A Spinazzi, Lina R Patel, Erika Chelales, Nicole Baumer, Peter Bulova, Brian Chicoine, Arturo Borzutzky, Hana M El Sahly, Joaquin M Espinosa, Melissa D Gans, Andrew A McCormick, Rebecca Partridge, Eric Rubenstein, Jonathan D Santoro, Cate Speake, Juanita Valdes Camacho, Kishore Vellody

引用次数: 0

Vaccine communication: a critical review of foundations, challenges, and future directions. 疫苗传播：对基础、挑战和未来方向的批判性审查。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-18 DOI: 10.1038/s41541-026-01487-9

Xiaoli Nan

引用次数: 0

β-Glucan chitosan particle provides cross-protection against multi-drug-resistant Candida auris. β-葡聚糖壳聚糖颗粒对多重耐药耳念珠菌具有交叉保护作用。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-16 DOI: 10.1038/s41541-026-01485-x

Shakti Singh, Ashley Barbarino, Eman G Youssef, Kaustav Das Gupta, Sunna Nabeela, Teclegiorgis Gebremariam, Sondus Alkhazraji, Priya Uppuluri, Garry Ostroff, Ashraf S Ibrahim

{"title":"β-Glucan chitosan particle provides cross-protection against multi-drug-resistant Candida auris.","authors":"Shakti Singh, Ashley Barbarino, Eman G Youssef, Kaustav Das Gupta, Sunna Nabeela, Teclegiorgis Gebremariam, Sondus Alkhazraji, Priya Uppuluri, Garry Ostroff, Ashraf S Ibrahim","doi":"10.1038/s41541-026-01485-x","DOIUrl":"10.1038/s41541-026-01485-x","url":null,"abstract":"Multidrug-resistant fungi, Candida auris, persist in the healthcare environment and colonize human skin and medical devices, causing life-threatening infections with mortality rates approaching ~60% in immunocompromised patients. Because some isolates are resistant to nearly all available antifungal drugs, alternative therapeutic approaches are urgently needed. C. auris cell wall contains β-glucan and highly conserved fungal glycan structures. Moreover, many cell wall proteins are heavily β-glycosylated, and a monoclonal antibody raised against β-glucan has been shown to recognize C. albicans hyphal-regulated cell wall protein (Hyr1p), which has homologous proteins in C. auris. Based on this conversation, we evaluated β-glucan chitosan particles (GCP) as a vaccine candidate and evaluated the humoral and cellular immune responses. GCP induced robust IgG antibody and IFN-γ, IL-4, and IL17 producing T cells that recognized purified C. auris cell wall proteins. Anti-GCP antibodies recognized the cell walls of C. auris isolates from four phylogenetic clades through binding to cell wall glycoproteins. Mice vaccinated with GCP were protected from disseminated C. auris infection (40% vs. 0% survival, p = <0.0001). GCP-vaccinated mice had significantly lower fungal burden than placebo in target organs (kidney, heart, and brain) and fewer fungal abscesses. These findings support GCP vaccination as a promising strategy against MDR C. auris.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13438728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147960220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developing a durable, memory-driven, CspZ-targeting Lyme disease vaccine by rational adjuvant selection. 通过合理的佐剂选择开发一种持久的、记忆驱动的、靶向cspz的莱姆病疫苗。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-16 DOI: 10.1038/s41541-026-01482-0

Miranda McCarty, Sergio A Hernández, Jill Malfetano, Ana Carolina Leão, Maria Jose Villar, Xiuli Yang, Yi-Lin Chen, Jungsoon Lee, Zhuyun Liu, Ulrich Strych, Maria Elena Bottazzi, Utpal Pal, Klemen Strle, Wen-Hsiang Chen, Yi-Pin Lin

{"title":"Developing a durable, memory-driven, CspZ-targeting Lyme disease vaccine by rational adjuvant selection.","authors":"Miranda McCarty, Sergio A Hernández, Jill Malfetano, Ana Carolina Leão, Maria Jose Villar, Xiuli Yang, Yi-Lin Chen, Jungsoon Lee, Zhuyun Liu, Ulrich Strych, Maria Elena Bottazzi, Utpal Pal, Klemen Strle, Wen-Hsiang Chen, Yi-Pin Lin","doi":"10.1038/s41541-026-01482-0","DOIUrl":"10.1038/s41541-026-01482-0","url":null,"abstract":"Rational adjuvant selection is a systematic approach based on adjuvant-mediated immunomodulation to identify safe vaccine regimens that enhance protective immunity. Transmitted through ticks and caused by the bacterium Borrelia burgdorferi (Bb), Lyme disease (LD) is the most common vector-borne disease in the Northern hemisphere. There are no approved human vaccines, making it suitable for testing the concept of rational adjuvant selection. Here, we formulated our previously developed and effective LD vaccine antigen, CspZ-YAC187S, with different adjuvants suitable for human use; we analyzed the immune response by transcriptomics and tested the vaccine efficacy after Bb infection. We identified Alum-CpG and Alum-αGal to elicit the highest titers of CspZ-YAC187S-dependent protective antibodies and robust levels of protection, but through distinct mechanisms of immunomodulation. We demonstrated that immunization with Alum-CpG formulated CspZ-YAC187S provided up to nine months of protective bactericidal antibody titers, as well as recall-memory response to prevent LD after natural infection. Immunity was linked to elevated levels of IgG1 memory cells in the vaccine-triggered immune responses. This work thus identified a durable, memory immunity-driven LD vaccine, ultimately paving the road to understand the mechanisms of rationale adjuvant selection for vaccine development.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147960090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0